TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms TACE-2
- 07 Jun 2016 Status changed from recruiting to discontinued as reported by results presented at the 52nd Annual meeting of the American Society of Clinical Oncology.
- 25 Feb 2016 Planned End Date changed from 31 Aug 2016 to 7 Dec 2015 as reported by united Kingdom clinical Research Network.
- 16 Feb 2016 Planned End Date changed from 7 Dec 2015 to 31 Aug 2016 as per ISRCTN: Current Controlled Trials record.